How does GBM AGILE work?, page-43

At least for CHM - I haven't looked at the other players - it is

• not in direct competition with newly diagnosed, unmethylated GBM - their IND and Phase I cover recurrent / relapsing GBM. Obviously they can always initiate a programme in newly diagnosed patients but for now they are not active in this sub-indication: http://www.chimerictherapeutics.com/wp-content/uploads/2021/08/IND-clearance-received-from-US-FDA-for-CHM-1101.pdf
• a good few years behind paxalisib: https://clinicaltrials.gov/ct2/show/NCT04214392

I remain upbeat on Kazia and continue to think that a conditional FDA approval based on the upcoming, final Phase II data is possible.